Xenetic Biosciences, Inc. (XBIO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Xenetic Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Xenetic Biosciences, Inc. (XBIO) has returned 23.50% so far this year and 2.68% over the past 12 months. Over the last ten years, XBIO has returned -45.79% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jun 30, 2014, XBIO's average daily return is +0.08%, while the average monthly return is -0.81%.

Historically, 47% of months were positive and 53% were negative. The best month was Jun 2018 with a return of +161.5%, while the worst month was Jul 2019 at -78.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, XBIO closed higher 40% of trading days. The best single day was Dec 9, 2020 with a return of +193.5%, while the worst single day was Jul 17, 2019 at -49.3%.

Xenetic Biosciences, Inc. has an annualized alpha of 13.87%, beta of 0.71, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 01, 2014.

• This stock participated in 234.34% of S&P 500 Index downside but only 3.92% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

XBIO ranks 49 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Xenetic Biosciences, Inc. (XBIO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Xenetic Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Xenetic Biosciences, Inc. was 99.95%, occurring on Dec 17, 2025. The portfolio has not yet recovered.

The current Xenetic Biosciences, Inc. drawdown is 99.93%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Xenetic Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Xenetic Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.